JP7235047B2 - アザベンゾイミダゾール化合物及び医薬 - Google Patents

アザベンゾイミダゾール化合物及び医薬 Download PDF

Info

Publication number
JP7235047B2
JP7235047B2 JP2020518289A JP2020518289A JP7235047B2 JP 7235047 B2 JP7235047 B2 JP 7235047B2 JP 2020518289 A JP2020518289 A JP 2020518289A JP 2020518289 A JP2020518289 A JP 2020518289A JP 7235047 B2 JP7235047 B2 JP 7235047B2
Authority
JP
Japan
Prior art keywords
methyl
pyridin
trifluoromethyl
imidazo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020518289A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019216294A5 (https=
JPWO2019216294A1 (ja
Inventor
幸也 及川
祥 平井
和彦 脇田
明子 藤林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of JPWO2019216294A1 publication Critical patent/JPWO2019216294A1/ja
Publication of JPWO2019216294A5 publication Critical patent/JPWO2019216294A5/ja
Application granted granted Critical
Publication of JP7235047B2 publication Critical patent/JP7235047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020518289A 2018-05-08 2019-05-07 アザベンゾイミダゾール化合物及び医薬 Active JP7235047B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018089867 2018-05-08
JP2018089867 2018-05-08
PCT/JP2019/018201 WO2019216294A1 (ja) 2018-05-08 2019-05-07 アザベンゾイミダゾール化合物及び医薬

Publications (3)

Publication Number Publication Date
JPWO2019216294A1 JPWO2019216294A1 (ja) 2021-05-13
JPWO2019216294A5 JPWO2019216294A5 (https=) 2023-01-19
JP7235047B2 true JP7235047B2 (ja) 2023-03-08

Family

ID=68467433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020518289A Active JP7235047B2 (ja) 2018-05-08 2019-05-07 アザベンゾイミダゾール化合物及び医薬

Country Status (35)

Country Link
US (1) US12319683B2 (https=)
EP (1) EP3792260B1 (https=)
JP (1) JP7235047B2 (https=)
KR (1) KR102819951B1 (https=)
CN (1) CN112368282B (https=)
AU (1) AU2019265134B2 (https=)
BR (1) BR112020022662A2 (https=)
CA (1) CA3099655A1 (https=)
CL (1) CL2020002868A1 (https=)
CO (1) CO2020013848A2 (https=)
DK (1) DK3792260T3 (https=)
EC (1) ECSP20078586A (https=)
ES (1) ES2992256T3 (https=)
FI (1) FI3792260T3 (https=)
HR (1) HRP20241414T1 (https=)
HU (1) HUE068695T2 (https=)
IL (1) IL278517B2 (https=)
LT (1) LT3792260T (https=)
MA (1) MA52587B1 (https=)
MD (1) MD3792260T2 (https=)
MX (1) MX2020011855A (https=)
MY (1) MY202833A (https=)
PE (1) PE20211384A1 (https=)
PH (1) PH12020551873A1 (https=)
PL (1) PL3792260T3 (https=)
PT (1) PT3792260T (https=)
RS (1) RS65996B1 (https=)
SA (1) SA520420487B1 (https=)
SG (1) SG11202011003TA (https=)
SI (1) SI3792260T1 (https=)
SM (1) SMT202400407T1 (https=)
TW (1) TWI868068B (https=)
UA (1) UA126774C2 (https=)
WO (1) WO2019216294A1 (https=)
ZA (1) ZA202007164B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600134B2 (ja) 2019-11-13 2024-12-16 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento
CN118045050B (zh) * 2023-11-16 2025-06-10 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法
WO2025153078A1 (zh) * 2024-01-17 2025-07-24 盛睿泽华医药科技（苏州）有限公司 可溶性环氧水解酶抑制剂及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510152A (ja) 2005-10-06 2009-03-12 ラボラトリオス・アルミラル・ソシエダッド・アノニマ Ａ２ｂアデノシン受容体アンタゴニストとしての、イミダゾピリジン誘導体
JP2011510044A (ja) 2008-01-24 2011-03-31 ユセベ ファルマ ソシエテ アノニム シクロブトキシ基を含む化合物
JP2012031152A (ja) 2010-06-28 2012-02-16 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物からなる医薬
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
JP2013545776A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
JP2016509048A (ja) 2013-02-20 2016-03-24 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ アスパラギンメチル転移酵素の阻害剤としての２−（ヘテロ）アリールベンゾイミダゾール及びイミダゾピリジン誘導体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723142A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1734820A4 (en) 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP6038150B2 (ja) 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤
JP2013237634A (ja) 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
EA031866B1 (ru) 2014-06-06 2019-03-29 Астеллас Фарма Инк. Производное 2-ациламинотиазола или его соль
BR112017003901A2 (pt) 2014-08-26 2017-12-12 Astellas Pharma Inc derivado de 2-aminotiazola ou sal do mesmo
JP6680297B2 (ja) 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CN115504986B (zh) 2017-03-03 2024-05-14 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
CA3085745A1 (en) 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
WO2019189766A1 (ja) 2018-03-30 2019-10-03 持田製薬株式会社 新規ビアリールアミド誘導体
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2021095805A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510152A (ja) 2005-10-06 2009-03-12 ラボラトリオス・アルミラル・ソシエダッド・アノニマ Ａ２ｂアデノシン受容体アンタゴニストとしての、イミダゾピリジン誘導体
JP2011510044A (ja) 2008-01-24 2011-03-31 ユセベ ファルマ ソシエテ アノニム シクロブトキシ基を含む化合物
JP2012031152A (ja) 2010-06-28 2012-02-16 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物からなる医薬
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
JP2013545776A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
JP2016509048A (ja) 2013-02-20 2016-03-24 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ アスパラギンメチル転移酵素の阻害剤としての２−（ヘテロ）アリールベンゾイミダゾール及びイミダゾピリジン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600134B2 (ja) 2019-11-13 2024-12-16 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤

Also Published As

Publication number Publication date
UA126774C2 (uk) 2023-02-01
DK3792260T3 (da) 2024-10-14
WO2019216294A1 (ja) 2019-11-14
TW202016108A (zh) 2020-05-01
KR20210006437A (ko) 2021-01-18
TWI868068B (zh) 2025-01-01
MA52587B1 (fr) 2024-10-31
US12319683B2 (en) 2025-06-03
IL278517B2 (en) 2024-09-01
IL278517B1 (en) 2024-05-01
EP3792260B1 (en) 2024-09-11
CL2020002868A1 (es) 2021-04-16
CA3099655A1 (en) 2019-11-14
MY202833A (en) 2024-05-24
PL3792260T3 (pl) 2024-12-02
SI3792260T1 (sl) 2024-11-29
PT3792260T (pt) 2024-10-02
MA52587A (fr) 2021-03-17
AU2019265134B2 (en) 2024-02-29
SG11202011003TA (en) 2020-12-30
PH12020551873A1 (en) 2021-05-31
ES2992256T3 (es) 2024-12-11
ECSP20078586A (es) 2021-01-29
MX2020011855A (es) 2021-01-20
CN112368282A (zh) 2021-02-12
LT3792260T (lt) 2024-10-25
US20210371412A1 (en) 2021-12-02
BR112020022662A2 (pt) 2021-02-09
CN112368282B (zh) 2023-10-13
EP3792260A1 (en) 2021-03-17
HRP20241414T1 (hr) 2024-12-20
AU2019265134A1 (en) 2020-12-17
KR102819951B1 (ko) 2025-06-13
IL278517A (en) 2020-12-31
FI3792260T3 (fi) 2024-10-01
EP3792260A4 (en) 2022-02-09
CO2020013848A2 (es) 2021-01-29
RS65996B1 (sr) 2024-10-31
MD3792260T2 (ro) 2024-12-31
HUE068695T2 (hu) 2025-01-28
SA520420487B1 (ar) 2024-03-17
ZA202007164B (en) 2024-06-26
PE20211384A1 (es) 2021-07-27
JPWO2019216294A1 (ja) 2021-05-13
SMT202400407T1 (it) 2024-11-15

Similar Documents

Publication Publication Date Title
JP7235047B2 (ja) アザベンゾイミダゾール化合物及び医薬
US12559506B2 (en) Indazole based compounds and associated methods of use
US8822448B2 (en) Pyrazoloquinoline compound
JP7600134B2 (ja) 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
JP7627661B2 (ja) アザベンゾイミダゾール化合物及び医薬
JP2021534256A (ja) 新規なヘテロサイクリックアミン誘導体およびこれを含む薬学組成物
RU2804485C2 (ru) Азабензимидазольные соединения и фармкомпозиция
JP2018154554A (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
JP2025526433A (ja) 治療に使用するためのｐａｒｐ１４の標的化タンパク質分解
HK40046611B (en) Azabenzimidazole compounds and pharmaceutical
HK40046611A (en) Azabenzimidazole compounds and pharmaceutical
KR20080050392A (ko) 대사성 글루타메이트 수용체 길항제로서 바이시클릭피페라진
HK40045733A (en) Azabenzimidazole compounds and pharmaceutical
US20240051946A1 (en) Targeted protein degradation of parp14 for use in therapy
HK40045733B (zh) 氮杂苯并咪唑化合物和医药
HK40076325A (en) Azabenzimidazole compound and medicine
HK40075503A (en) Azabenzimidazole compound and medicine
WO2021187605A1 (ja) 含窒素複素環αシアノカルボニル化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230206

R150 Certificate of patent or registration of utility model

Ref document number: 7235047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250